Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALTERITY THERAPEUTICS LTDATHE · Entity 6880 | Director · Chief Executive Officer | August 31, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALTERITY THERAPEUTICS LTD
Report date August 31, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Listed option exp 31 Aug 2026SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2026-08-31 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Purchase · Disposed 47,620 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 8, 2026 22:52 UTC | ALTERITY THERAPEUTICS LTD ATHE · Entity 6880 | PurchaseListed option exp 31 Aug 2026 · Derivative | 47,620 | $0.50 Strike: $0.50 | $23,810.00 |
DisclosureSEC source: 0002130205-26-000002 · primary_doc.xml · derivative · entry 1 Stamler David Allen · CIK 0002130205 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 47,620 shares Expires 2026-08-31 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.